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Graft versus tumor eﬀect has been described in solid metastatic tumor. We reported here the case of a patient treated for an acute
myeloid leukemia with reduced-intensity conditioned allograft and the eﬀect of this procedure on concomitant of renal localised
cancer. The eﬀect of immune-mediated cytotoxicity on renal cancer is the more consistent explanation to understand the necrosis
of this tumor. Any case of RIC allograft has been reported before to treat localised renal tumor.
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1.Introduction
The eﬀect of immune-mediated cytotoxicity on renal cancer
has been clearly outlined in the last decades by several lines
of evidence. We reported here a patient with bone marrow
failure treated with RIC allograft and the eﬀect of this
procedure on a concomitant localised renal cancer.
2.CaseReport
A 52-year-old man was referred in 1980 in our
department because of severe pancytopenia (platelets:
8G/L; hemoglobin: 8.3g/d; MCV: 87ﬂ, reticulocytes:
0.5% (14000/microL); WBC : 2.1G/L; Neutrophils: 16%;
Lymphocytes: 70%; Monocytes: 4%). Bone marrow was
aplastic on histological examination. He was then treated
with packed red cells and platelets transfusions and horse
antithymocyte globulin with a full response. The disease
relapsed in 1997 with the same presentation. After an
ineﬀective course of ciclosporin, a partial response was
obtained with a second course of rabbit antithymocyte
globulin and high dose androgen therapy. Subsequently,
myelodysplasic features appeared with chromosome 7
monosomy, which evolved to a smouldering transformation
in AML 6 in April 2004.
At the same time, a left kidney tumor (46 × 42mm)
was discovered on computer tomography scan (Figure 1).
This renal mass was interpreted as a clear cell carcinoma.
However, given the slow progression of the tumor and the
poor haematological status, biopsy and nephrectomy was
ﬁrst diﬀered. In June 2005, a reduced-intensity conditioned
(RIC) allograft was performed with an unrelated stem cell
donor mismatched on DRB3 antigen and on split Cw. The
preparative regimen consisted of 30mg/m2 of ﬂudarabine
on days -1, -2 and -3 and total body irradiation at 2 grays on
day -1. The patient received a dose of 6.11 × 106CD34/kg.
Prevention of graft versus host disease was based on
ciclosporine 3mg/kg/day started at day 1 and switched on
day 6 on mycophenolate mofetil 15mg/kg twice a day and
prednisone 1mg/kg/day because of an increasing plasma
creatinine.
The immediate course was uneventful with a complete
full donor-type haematological reconstitution on day 42. At
this time, prednisolone was decreased; on day 85, a skin
and gut grade II acute graft versus host disease developed
which was treated with high dose methylprednisolone and
mycophenolate mophetil. At that time, the left kidney tumor
measured 50mm and his aspect remained unchanged on CT
scan.AcuteGVHDquicklyresolvedandinMay2006chronic2 Case Reports in Medicine
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Figure 1: CT scan showing left renal tumor before RIC HSCT.
skin and pulmonary GVHD developed. Subsequent scans
showed stability of the renal tumor.
Finally, in September 2006, as the patient has recovered
a good clinical and haematological status (haemoglobin:
13.1g/dL; platelets: 110G/L; leucocytes: 5.1G/L with normal
diﬀerential count), a left nephrectomy was performed. The
tumor size was 60mm × 40mm. On histological analysis,
the tumor process was fully necrosed. Adjacent kidney
parenchyma was normal, kidney veins were free of tumor
and no metastasis disease was found.
3. Discussion
In this case, we could not document precisely the histological
type of this kidney cancer, as it was completely necrosed at
time of nephrectomy. However, the aspect on the CTscan is
favoring the diagnosis of renal cell carcinoma with a strong
evidence.
The mechanism accounting for the tumor regression
deserves discussion. The tumor necrosis was delayed nine
monthsaftertheadministrationoftheallograftconditioning
regimen.
Spontaneous tumor regression can be hypothesised, but
the true incidence of this phenomenon is probably less
than 1% and the majority of documented spontaneous
regressions involve metastasis spread of renal cell carcinoma,
not primitive tumor.
An immune-mediated necrotic process of the kidney
cancer is a more consistent explanation in this case. This
phenomenon has been clearly illustrated by several lines
of evidence in the past. Rosenberg et al. [1] have studied
the eﬀects of adoptive immunotherapy with lymphocyteac-
tivated killer (LAK) cells plus interleukin-2 in 157 patients
withmetastaticcancerinwhich36whohadrenal-cellcancer.
Among 36 evaluable patients treated with LAK cells plus
interleukin 2, 12 objective tumor regressions were observed.
Brouwenstijn et al. [2] have isolated and characterized
tumor speciﬁc CTL from peripheric blood lymphocytes in
a patient with RCC and from tumor inﬁltrating lymphocytes
from an other one. This data supports the assumption that
common RCC tumor antigens could be recognized by CTL.
Similarly, there is some evidence that bone marrow
transplant could reverse the spread of metastatic renal cell
carcinoma [3]. Barkholt et al. [4] reviewed 124 patients
with metastatic renal cell carcinoma, who received RIC
HSCT, have noticed a tumor spread improvement after the
procedure in 29% of these cases.
Posttransplant DLI and chronic GVHD improved the
patient’s survival. TRM was 16%, patients with less than
three metastatic locations and a Karnofsky score >70%
clearly had a beneﬁt from HSCT. Childset al. [5]h a v e
reported similar results on a groups of 19 patients. On
the other hand, Rini et al. [6], reporting on twenty-two
patientswithadvancedrenalcellcarcinomatreatedbyHSCT,
observe no objective cancer response, despite the occurrence
of chronic GVHD. They explained these poor results by a
selection of patients with advanced and bulky disease at the
time of the grafting, limiting the GVT eﬀect.
A direct cytotoxic eﬀect involving donor lymphocytes
issued from the graft is a consistant hypothesis. Harlin et al.
[7] have observed in 15 RCC patients treated with RIC
allograft, increasing ratio of CD8+ to CD4 T cells, and
production of gamma-IFN and IL-2 at the time of clinical
responses (generally on day 180 after transplantation).
Tykodi et al. [8], monitoring 8 patients, after an RIC
HSCT for metastatic renal cell carcinoma, demonstrated the
presence of CD8+ CTL able to recognize minor H antigens
on tumors cells and hypothesized that these cells could
contributetotheGVTeﬀect.OnRCCmurinemodelstreated
with HSCT, Horano et al. [9] have shown that most of the
tumor inﬁltrating lymphocytes were host-derived cells. The
level of donorderived lymphocytes gradually decreased over
time and was undetectable 120 days after DLI.
In our patient, such a mechanisme remains the more
consistent explanation. To our knowledge, a complete necro-
sis of a localised renal tumor in relation with RIC allograft
eﬀect has not been previously reported.
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